Online citations, reference lists, and bibliographies.

Prognostic Value Of 18F-FDG PET Metabolic Parameters In Oropharyngeal Squamous Cell Carcinoma

Adam A. Garsa, Albert J. Chang, Todd A DeWees, Christopher R. Spencer, Douglas R. Adkins, Farrokh Dehdashti, Hiram A. Gay, Wade L. Thorstad
Published 2012 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
ObjectiveTo evaluate whether pretreatment metabolic parameters obtained from positron emission tomography (PET) with [18F]fluorodeoxyglucose (FDG) can improve risk prediction for patients with oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive intensity-modulated radiation therapy (IMRT).MethodsBetween 2003 and 2009, 86 patients with OPSCC had FDG-PET/CT prior to treatment with definitive IMRT. Chemotherapy was administered to 90 % of the patients. Metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value (SUVmax), mean SUV (SUVmean), and inverse coefficient of variation (1/CoV) were analyzed for the primary tumor alone and the total of the primary tumor and involved lymph nodes.ResultsMedian follow-up time for surviving patients was 41 months. On univariate analysis, total MTV and total TLG were significant predictors of disease-free survival (DFS) and overall survival (OS). SUVmax, SUVmean, and 1/CoV failed to predict DFS or OS. On multivariate analysis controlling for T- and N-classification, total MTV remained a significant predictor of DFS and OS. The optimal cutpoint for total MTV was 20.5 ml. A total MTV >20.5 ml was associated with a 4.13-fold increased risk of death (95 % confidence interval [CI], 2.12–8.05; p < 0.0001). Total MTV remained a significant predictor of DFS and OS for the subgroups with p16-positive (n = 25) and p16-negative (n =18) cancer.ConclusionTotal MTV is an independent predictor of DFS and OS for patients with OPSCC treated with definitive radiotherapy. Total MTV remained predictive of DFS and OS for both p16-positive and p16-negative cancer.
This paper references
10.1016/j.ijrobp.2010.11.050
Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
Kristin Higgins (2012)
Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes
Brent A. Williams (2006)
10.1016/j.ijrobp.2006.01.014
Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET/CT fusion.
Adam C. Riegel (2005)
10.1016/j.radonc.2011.02.010
The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial.
Pernille Lassen (2011)
10.1002/hed.22904
Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters.
Seung Hwan Moon (2013)
10.1016/j.semradonc.2006.04.006
Is PET-based treatment planning the new standard in modern radiotherapy? The head and neck paradigm.
Vincent Grégoire (2006)
10.1016/S1095-0397(99)00016-3
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.
Steven M. Larson (1999)
10.3109/02841860903440270
Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy
Young Mi Seol (2010)
10.1016/S0098-1672(09)79396-8
Spatial Heterogeneity in Sarcoma 18F-FDG Uptake as a Predictor of Patient Outcome
Betty Jean Manaster (2010)
10.1016/j.ijrobp.2007.07.2333
Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer.
Dominic A. X. Schinagl (2007)
10.1007/s00259-011-1845-6
Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies
Floris H P van Velden (2011)
10.1093/annonc/mdr006
Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial.
Marshall R. Posner (2011)
10.1016/j.ijrobp.2011.10.023
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.
Chad Tang (2012)
10.1016/J.YPED.2010.12.093
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
James A. Stockman (2012)
10.1158/1078-0432.CCR-08-3290
Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer
Man Ki Chung (2009)
10.1001/archotol.130.12.1361
FDG-PET prediction of head and neck squamous cell cancer outcomes.
David L. Schwartz (2004)
10.1186/1758-3284-2-19
FDG-PET staging and importance of lymph node SUV in head and neck cancer
Gregory J Kubicek (2010)
10.1158/1078-0432.CCR-07-5252
Intratumoral Metabolic Heterogeneity of Cervical Cancer
Elizabeth A Kidd (2008)
10.1016/S0360-3016(03)00346-8
Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study.
I. Frank Ciernik (2003)
10.1016/j.ijrobp.2008.10.060
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer.
Trang H. La (2008)
10.2967/jnumed.108.053397
Spatial Heterogeneity in Sarcoma 18F-FDG Uptake as a Predictor of Patient Outcome
Janet F Eary (2008)



This paper is referenced by
10.1002/hed.23929
Multimodal imaging analysis of an orthotopic head and neck cancer mouse model and application of anti-CD137 tumor immune therapy.
Anne-Kristin Vahle (2016)
10.1088/1361-6560/aa73cc
Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics.
Michael R. Folkert (2017)
10.1007/s12032-019-1318-5
nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma
Kai C. C. Johnson (2019)
10.1097/RLU.0000000000000780
Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Metastatic Differentiated Thyroid Cancers
Soizic Masson-Deshayes (2015)
10.1016/j.radonc.2019.05.019
The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status.
Jon M Moan (2019)
10.1111/1754-9485.12439
18F-FDG PET-CT performed before and during radiation therapy of head and neck squamous cell carcinoma: Are they independent or complementary to each other?
Myo Min (2016)
10.1002/hed.23920
Interaction of quantitative (18)F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma.
Charlotte S. Schouten (2016)
10.1097/MNM.0000000000000208
18F-FDG PET/CT as a semiquantitative imaging marker in HPV-p16-positive oropharyngeal squamous cell cancers
Yu-Ting Huang (2015)
10.1002/lary.28509
Outcomes and Predictive Value of Post-adjuvant Therapy PET/CT for Locally Advanced Oral Squamous Cell Carcinoma.
David C. Qian (2020)
10.1007/s12094-017-1674-6
Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma
Jon Cacicedo (2017)
18-F-FDG as a Semi-quantitative Imaging Marker in HPV-p 16 positive Oral Cavity and Oropharyngeal Squamous Cell Cancer
Y.-T. Huang (2013)
10.1016/j.cpet.2014.09.003
PET-based radiation therapy planning.
Christina K. Speirs (2015)
10.1097/RLU.0000000000002531
The Prognostic Value of Baseline 18F-FDG PET/CT in Human Papillomavirus–Positive Versus Human Papillomavirus–Negative Patients With Oropharyngeal Cancer
Zeno A. R. Gouw (2019)
10.1002/hed.25337
Pretreatment metabolic tumor volume as a prognostic factor in HPV‐associated oropharyngeal cancer in the context of AJCC 8th edition staging
John M Floberg (2018)
10.1007/s11604-017-0686-z
Prognostic value of volumetric FDG PET/CT parameters in patients with oral tongue squamous cell carcinoma who were treated by superselective intra-arterial chemoradiotherapy
Satoko Suzuki-Shibata (2017)
10.1001/jamaoto.2015.2607
Use of 18F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography for Patient Management and Outcome in Oropharyngeal Squamous Cell Carcinoma: A Review.
Mehdi Taghipour (2016)
10.1155/2019/4627521
How Effective Are Noninvasive Tests for Diagnosing Malignant Peripheral Nerve Sheath Tumors in Patients with Neurofibromatosis Type 1? Diagnosing MPNST in NF1 Patients
Maria T Schwabe (2019)
10.2967/jnumed.113.133801
Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-Analysis
Kyoungjune Pak (2014)
10.18999/nagjms.79.1.27
[18F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcomes for oropharyngeal and hypopharyngeal cancer treated with definitive radiotherapy
Takeaki Ishihara (2017)
10.1111/1754-9485.12496
A review of the predictive role of functional imaging in patients with mucosal primary head and neck cancer treated with radiation therapy
Myo Min (2017)
10.1002/hed.24488
Prognostic significance of metabolic tumor volume in patients with piriform sinus carcinoma treated by radiotherapy with or without concurrent chemotherapy.
Kenichiro Yabuki (2016)
10.1016/j.oraloncology.2018.09.018
Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach: A systematic review and meta-analysis.
Parul Khare Sinha (2018)
10.1371/journal.pone.0117924
Predictive and Prognostic Value of Metabolic Tumor Volume (MTV) in Patients with Laryngeal Carcinoma Treated by Radiotherapy (RT) / Concurrent Chemoradiotherapy (CCRT)
Kenichiro Yabuki (2015)
10.1259/BJR.20160217
Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.
Jon Cacicedo (2016)
Semantic Scholar Logo Some data provided by SemanticScholar